Lung Cancer
November 10
10 min read
Updated findings from Stage 1 of the multicenter, international, two-stage phase III PRESERVE-003 trial showed that, among patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease had progressed following anti–PD-(L)1 therapy, treatment with the investigational anti–CTLA-4 monoclonal antibody gotistobart nearly doubled median overall survival vs docetaxel. Clinical pharmacology data also appeared to support the selected dosing regimen, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer.